Abstracts
Abstract submissions for BRiM 2026 are now closed.
The BRiM Summit format will differ slightly from the traditional conference format previously used within the Why Study Mammographic Density? Conference. In addition to expert presentation, each session will include bi-directional sharing of ideas and at least one interactive component to generate more tangible outcomes. This could include panel discussions to facilitate consensus on guidance for clinical practice, case studies to inform and test proposed clinical guidance, or qualitative research methods to prioritise future action or recommendations for research and/or policy change.
To facilitate this interactive scientific program, we are offering two rounds of Abstract submissions for presentation at the BRiM Summit:
- Targeted calls for Abstracts
- General call for Abstracts
Targeted calls for Abstracts reflect the specific topics to be covered during the Summit. Open invitation for Abstracts includes all other topics that relate to new or ongoing research in breast cancer risk or the management of breast cancer risk.
Targeted calls:
Foundations of breast cancer risk management
We are inviting abstracts that provide an overview of the foundations of breast cancer risk management to ensure the audience has equal access to information, regardless of experience or discipline. This includes:
- Risk perception, including risk communication, health promotion strategies, and consumer-informed research
- Risk assessment, including clinical risk factor risk prediction tools, AI-derived mammogram risk scores, polygenic risk scores, and/or blood-based risk scores.
- Risk reducing strategies, including what is known about the biology of prevention
- Risk-stratified screening, including ongoing approaches and primary care perspectives towards more personalised screening
Community representatives, PhD Students, early-career researchers, and screening professionals are strongly encouraged to submit targeted abstracts for this session. The Abstract format is flexible and can be up to 500 words. Inclusion of a Table or Figure is encouraged.
Managing Risks: Guidance for General Practitioners and Breast Specialists
We are inviting abstracts that provide guidance for health practitioners regarding:
- the use of endocrine therapy for high-risk women.
- the use of hormone replacement therapy for women at different levels of breast cancer risk and/or with dense breasts.
- supplemental screening recommendations for women at increased risk and/or with dense breasts.
Abstracts should include a table/flowchart that outlines the guidance, a 250-word justification, and up to 10 references.
Innovation
We are inviting abstracts that describe cutting-edge research regarding:
- risk prediction, including performance and/or integration of risk prediction algorithms/tools
- the biology of prevention, including the use of biological and/or genetic data to identify those at higher risk and/or develop pharmacological solutions
Standard 250-word Abstracts should include Background, Methods, Results and Conclusion.
Risk management within underserved populations
We are inviting abstracts that describe screening in marginalised populations, including participation, cancer outcomes, validation/calibration of risk prediction tools, health promotion strategies, structural barriers, equity of access, and communication of risk.
Standard 250-word Abstracts should include Background, Methods, Results and Conclusion.
Implementation challenges for breast cancer risk management
We are inviting abstracts that describe challenges in implementing advances in breast cancer risk management into clinical practice, including clinical workflow and practice issues, awareness and education challenges, accuracy and standardisation of risk prediction tools, and systemic and structural challenges. Standard 250-word Abstracts should include Background, Methods, Results and Conclusion.
General Abstracts
We are inviting standard 250-word Abstracts that describe new or ongoing research in all other areas of breast cancer risk management within asymptomatic individuals (including those with a previous breast cancer diagnosis). Abstracts should include Background, Methods, Results and Conclusion.